Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center
Abstract Introduction Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. There is a paucity of studies that have comprehensively analyzed the clinical and laboratory profiles of B-ALL patients showing aberrant T/natural killer (NK) cell antigen expression. Materials and methods This is a prospective study where 152 consecutive B-ALL patients were analyzed for aberrant expression of T/NK cell antigens (CD1a, CD5, CD4, CD7, CD8 and CD56) by FCI. The clinical and laboratory profile of these T/NK-cell antigen-expressing B-ALL patients was statistically analyzed against conventional B-ALL patients. Results In our B-ALL cohort, CD5, CD7 and CD56 expression were observed in one, six and nine patients, respectively. CD56-expressing B-ALL patients were predominantly children (89%) and presented as standard clinical risk (p = 0.010) disease with frequent ETV6-RUNX1 fusion (p = 0.021) positivity. On the contrary, CD7-expressing B-ALL patients were adolescent-young adult/adult-age skewed (83%) and had an adverse cytogenetic profile (p = 0.001), especially for the frequent presence of BCR-ABL1 fusion (p = 0.004) and KMT2A rearrangement (p = 0.045). CD7-expressing B-ALL patients had inferior event-free survival (p = 0.040) than their CD56-expressing counterparts, but there was no significant difference in the overall survival (p = 0.317). Conclusion In comparison to conventional B-ALL patients, there are significant differences in the age, cytogenetic profile and event-free survival of T/NK-cell antigen-expressing B-ALL patients.
Main Authors: | , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
2022
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000200143 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S2531-13792022000200143 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S2531-137920220002001432022-06-08Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care centerBommannan,KarthikArumugam,Jhansi RaniRadhakrishnan,VenkatramanKalaiyarasi,Jayachandran PerumalMehra,NikitaSagar,Tenali GnanaSundersingh,Shirley CD56 positive precursor B lineage acute lymphoblastic leukemia CD7 positive precursor B lineage acute lymphoblastic leukemia Precursor B lineage acute lymphoblastic leukemia Abstract Introduction Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. There is a paucity of studies that have comprehensively analyzed the clinical and laboratory profiles of B-ALL patients showing aberrant T/natural killer (NK) cell antigen expression. Materials and methods This is a prospective study where 152 consecutive B-ALL patients were analyzed for aberrant expression of T/NK cell antigens (CD1a, CD5, CD4, CD7, CD8 and CD56) by FCI. The clinical and laboratory profile of these T/NK-cell antigen-expressing B-ALL patients was statistically analyzed against conventional B-ALL patients. Results In our B-ALL cohort, CD5, CD7 and CD56 expression were observed in one, six and nine patients, respectively. CD56-expressing B-ALL patients were predominantly children (89%) and presented as standard clinical risk (p = 0.010) disease with frequent ETV6-RUNX1 fusion (p = 0.021) positivity. On the contrary, CD7-expressing B-ALL patients were adolescent-young adult/adult-age skewed (83%) and had an adverse cytogenetic profile (p = 0.001), especially for the frequent presence of BCR-ABL1 fusion (p = 0.004) and KMT2A rearrangement (p = 0.045). CD7-expressing B-ALL patients had inferior event-free survival (p = 0.040) than their CD56-expressing counterparts, but there was no significant difference in the overall survival (p = 0.317). Conclusion In comparison to conventional B-ALL patients, there are significant differences in the age, cytogenetic profile and event-free survival of T/NK-cell antigen-expressing B-ALL patients.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)Hematology, Transfusion and Cell Therapy v.44 n.2 20222022-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000200143en10.1016/j.htct.2020.08.012 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Bommannan,Karthik Arumugam,Jhansi Rani Radhakrishnan,Venkatraman Kalaiyarasi,Jayachandran Perumal Mehra,Nikita Sagar,Tenali Gnana Sundersingh,Shirley |
spellingShingle |
Bommannan,Karthik Arumugam,Jhansi Rani Radhakrishnan,Venkatraman Kalaiyarasi,Jayachandran Perumal Mehra,Nikita Sagar,Tenali Gnana Sundersingh,Shirley Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center |
author_facet |
Bommannan,Karthik Arumugam,Jhansi Rani Radhakrishnan,Venkatraman Kalaiyarasi,Jayachandran Perumal Mehra,Nikita Sagar,Tenali Gnana Sundersingh,Shirley |
author_sort |
Bommannan,Karthik |
title |
Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center |
title_short |
Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center |
title_full |
Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center |
title_fullStr |
Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center |
title_full_unstemmed |
Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center |
title_sort |
precursor b-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and t cell - lineage antigen expression: experience from a tertiary cancer care center |
description |
Abstract Introduction Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. There is a paucity of studies that have comprehensively analyzed the clinical and laboratory profiles of B-ALL patients showing aberrant T/natural killer (NK) cell antigen expression. Materials and methods This is a prospective study where 152 consecutive B-ALL patients were analyzed for aberrant expression of T/NK cell antigens (CD1a, CD5, CD4, CD7, CD8 and CD56) by FCI. The clinical and laboratory profile of these T/NK-cell antigen-expressing B-ALL patients was statistically analyzed against conventional B-ALL patients. Results In our B-ALL cohort, CD5, CD7 and CD56 expression were observed in one, six and nine patients, respectively. CD56-expressing B-ALL patients were predominantly children (89%) and presented as standard clinical risk (p = 0.010) disease with frequent ETV6-RUNX1 fusion (p = 0.021) positivity. On the contrary, CD7-expressing B-ALL patients were adolescent-young adult/adult-age skewed (83%) and had an adverse cytogenetic profile (p = 0.001), especially for the frequent presence of BCR-ABL1 fusion (p = 0.004) and KMT2A rearrangement (p = 0.045). CD7-expressing B-ALL patients had inferior event-free survival (p = 0.040) than their CD56-expressing counterparts, but there was no significant difference in the overall survival (p = 0.317). Conclusion In comparison to conventional B-ALL patients, there are significant differences in the age, cytogenetic profile and event-free survival of T/NK-cell antigen-expressing B-ALL patients. |
publisher |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) |
publishDate |
2022 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000200143 |
work_keys_str_mv |
AT bommannankarthik precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT arumugamjhansirani precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT radhakrishnanvenkatraman precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT kalaiyarasijayachandranperumal precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT mehranikita precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT sagartenalignana precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT sundersinghshirley precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter |
_version_ |
1756442083764207616 |